CoChat
Sign Up
Cited by 3Bariatric Surgery and OutcomesCardiomyopathy and Myosin StudiesHeart Failure Treatment and Management

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis

Mahmoud, Ahmed K, Awad, Kamal, Sheashaa, Hesham, Kandil, Omneya, Farina, Juan M, Ibrahim, Ramzi, Abdelnabi, Mahmoud, Allam, Mohamed, Mital, Rohit, Shipman, Justin, Alsidawi, Said, Lester, Steven J, Ommen, Steve R, Geske, Jeffrey B, Patten, Richard, Ayoub, Chadi, Arsanjani, Reza·2026·European Heart Journal - Quality of Care and Clinical Outcomes
DOI 10.1093/ehjqcco/qcag051
Open this paper in CoChat — free account

Abstract

Aims: Obesity is linked with worse outcomes in hypertrophic cardiomyopathy (HCM). While both bariatric surgery (BS) and GLP-1 receptor agonists (GLP-1RA) promote weight loss and may improve cardiometabolic risk, their comparative outcomes in HCM remain unclear. Methods and results: Adults with HCM and body mass index (BMI) ≥ 30 kg/m were divided into two cohorts: (i) GLP-1 RA users who never had BS, and (ii) BS patients who never received GLP-1 RA. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and medications. Outcomes over 24 months include all-cause mortality, acute heart failure (HF) hospitalization, arrhythmias, change in BMI, and cardiovascular symptoms. Hazard ratios with 95% confidence intervals were estimated using Cox models. Of 5002 patients, 955 were included in each matched cohort after matching (mean age 54 ± 13 years, 70% female, BMI 40.0 kg/m). GLP-1 RA was associated with a significantly lower observed rate of all-cause mortality compared with BS (2.0% vs. 4.4%; HR 0.46; 95% CI 0.27–0.80; P = 0.004) and HF hospitalization (8.7% vs. 14.0%; HR 0.60; 95% CI 0.46–0.79; P < 0.001). Similarly, GLP-1 RA use was associated with a lower incidence of composite cardiovascular outcomes (10.7% vs. 17.2%; HR 0.60; 95% CI 0.47–0.77; P < 0.001). Rates of arrhythmia and cardiovascular symptoms were comparable between the two groups. BMI reduction was greater after bariatric surgery (−4.0 vs. −2.6 kg/m; P < 0.001). Conclusion: In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.

Overview

Integrity signals

Registry

Crossref · 10.1093/ehjqcco/qcag051

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Wang, 2015, [Effects of GLP-1 agonist exenatide on cardiac diastolic function and vascular endothelial function in diabetic patients], Sichuan Da Xue Xue Bao Yi Xue Ban, 46, 586

Cited by

Sorted by citations

Related

Metadata

Authors
Mahmoud, A. K., Awad, K., Sheashaa, H., Kandil, O., Farina, J. M., Ibrahim, R., Abdelnabi, M., Allam, M., Mital, R., Shipman, J., Alsidawi, S., Lester, S. J., Ommen, S. R., Geske, J. B., Patten, R., Ayoub, C., & Arsanjani, R.
Affiliations
  • Boston Medical Center (US)
  • Mayo Clinic (US)
Corresponding author
Mahmoud, Ahmed K
ORCID
Venue
European Heart Journal - Quality of Care and Clinical Outcomes
Publisher
Oxford University Press (OUP)
Published
2026-03-30
Volume
12
Issue
5
Pages
731-739
ISSN
  • 2058-1742 (ISSN-L)
  • 2058-5225
DOI
10.1093/ehjqcco/qcag051
OpenAlex
W7143519800
Cited by
3
References
24
Citations by year
2026: 3
FWCI
14.69
Type
journal article
Language
en
Open access
closed
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • European Heart Journal - Quality of Care and Clinical Outcomes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
hypertrophic cardiomyopathy, obesity, GLP-1 receptor agonists, bariatric surgery, all-cause mortality, heart failure hospitalization, cardiac arrhythmias, body mass index reduction, cardiovascular outcomes, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Cardiomyopathy, Hypertrophic, Female, Humans, Male, Middle Aged, Obesity, Retrospective Studies, Body Mass Index, Treatment Outcome, Bariatric Surgery, Propensity Score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review